Spoken Alpha
NRXPW
NRX Pharmaceuticals, Inc.
Overview
NRx Pharmaceuticals develops novel therapeutics for central nervous system disorders including suicidal depression, PTSD, chronic pain, and schizophrenia. The company's lead candidates—NRX-100 and KETAFREE (preservative-free ketamine formulations) and NRX-101 (an oral combination of D-cycloserine and lurasidone)—are in FDA review for approval.
NRX Pharmaceuticals, Inc has a $714.6M market cap.
Most recent reported earnings: Q2 FY2021 (Sep 29, 2021).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-05-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-1811 Q&A exchanges
- Q4 FY2025Earnings2026-03-246 Q&A exchanges
- Q3 FY2025Earnings2025-11-177 Q&A exchanges
- Q2 FY2025Earnings2025-08-208 Q&A exchanges
- Q1 FY2025Earnings2025-05-164 Q&A exchanges
- Q4 FY2024Earnings2025-03-1718 Q&A exchanges
- Q3 FY2024Earnings2024-11-1810 Q&A exchanges
- Q2 FY2024Earnings2024-08-154 Q&A exchanges
- Q1 FY2024Earnings2024-05-146 Q&A exchanges
- Q4 FY2023Earnings2024-04-015 Q&A exchanges
- Q3 FY2023Earnings2023-11-143 Q&A exchanges
- Q2 FY2023Earnings2023-08-143 Q&A exchanges
- Q1 FY2023Earnings2023-05-169 Q&A exchanges
- Q4 FY2022Earnings2023-03-3018 Q&A exchanges
- Q3 FY2022Earnings2022-11-147 Q&A exchanges
- Q2 FY2022Earnings2022-08-152 Q&A exchanges
- Q1 FY2022Earnings2022-05-16
- Q4 FY2021Earnings2022-03-31
- Q3 FY2021Earnings2021-11-16
- Q2 FY2021Earnings2021-08-171 Q&A exchange
History
Earnings history
- Q2 FY20212021-09-29EPS$-0.40 vs $0.00—Rev$0 vs ——EODHD
- Q1 FY20212021-06-29EPS$-6.51 vs $0.00—Rev$-113.1K vs ——EODHD
- Q4 FY20202021-03-30EPS$-2.26 vs $0.00—Rev— vs ——EODHD
- Q2 FY20202020-09-29EPS$-0.15 vs $0.00—Rev$25.0K vs ——EODHD
- Q1 FY20202020-06-29EPS$0.00 vs $0.00—Rev$113.1K vs ——EODHD
- Q4 FY20192020-03-30EPS$-0.15 vs $0.00—Rev$172.3K vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2021 | 2021-09-29 | $-0.40 | $0.00 | — | $0 | — | — | EODHD |
| Q1 FY2021 | 2021-06-29 | $-6.51 | $0.00 | — | $-113.1K | — | — | EODHD |
| Q4 FY2020 | 2021-03-30 | $-2.26 | $0.00 | — | — | — | — | EODHD |
| Q2 FY2020 | 2020-09-29 | $-0.15 | $0.00 | — | $25.0K | — | — | EODHD |
| Q1 FY2020 | 2020-06-29 | $0.00 | $0.00 | — | $113.1K | — | — | EODHD |
| Q4 FY2019 | 2020-03-30 | $-0.15 | $0.00 | — | $172.3K | — | — | EODHD |
Source: EODHD. NRXPW reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks NRXPW's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 5/10 quarters with 70% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Missed in 2 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.34 | $2.44 | -4.3% | -2.4% | -3.9% |
| Q4 FY2026 | $2.78 | $2.67 | +4.2% | +2.6% | +1.6% |
| Q3 FY2026 | $2.81 | $2.58 | +9.0% | +3.8% | +4.0% |
| Q2 FY2026 | $2.69 | $2.74 | -2.0% | -4.0% | -6.7% |
| Q1 FY2025 | $2.66 | $2.71 | -1.8% | +2.3% | +2.5% |
| Q4 FY2025 | $2.53 | $2.64 | -4.2% | +0.4% | -2.1% |
| Q3 FY2025 | $2.61 | $2.59 | +0.6% | +1.3% | -0.6% |
| Q2 FY2025 | $2.90 | $2.74 | +5.8% | -2.5% | +0.5% |
| Q1 FY2024 | $3.08 | $2.88 | +7.0% | +1.6% | +0.3% |
| Q4 FY2024 | $2.66 | $2.72 | -2.2% | +0.9% | +0.3% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Maintained2026-07-15
- Q1 FY2025Maintained2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Maintained2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Joseph Michael CasperCOO5 mono recorded callsCurrentSample
COO since 2026 • 2/2 beats (100%) • last guidance cut Q1 FY2026
- Stephen H WillardCEO0 mo9 callsFormerSample
CEO since 2022 • 7/16 beats (44%) • last call held guidance Q2 FY2026
- Michael S AbramsCFO3 mo7 callsFormerSample
CFO since 2024 • 4/8 beats (50%) • last call held guidance Q2 FY2026
- Richard Clavano NaridoCFO0 mono recorded callsFormerSample
CFO since 2023 • 7/12 beats (58%) • last guidance cut Q2 FY2026
- Voorhees Seth VanCFO1 mono recorded callsFormerSample
CFO since 2022 • 13/16 beats (81%) • last call held guidance Q1 FY2026
- Ira S StrassbergCFO0 mo2 callsFormerSample
CFO since 2022 • 6/16 beats (38%) • last call held guidance Q3 FY2026
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NRXPW.
$ curl https://api.spokenalpha.com/v1/companies/NRXPWFAQ
Frequently asked about NRXPW
Where can I find NRX Pharmaceuticals, Inc.'s (NRXPW) earnings call transcripts?
Spoken Alpha indexes NRXPW's earnings call transcripts at https://spokenalpha.com/companies/NRXPW. Each call links to attributed speakers and parsed analyst Q&A. NRX Pharmaceuticals, Inc.'s own investor relations page is at https://ir.nrxpharma.com/.
When was NRX Pharmaceuticals, Inc.'s most recent earnings call?
NRX Pharmaceuticals, Inc. (NRXPW) held its most recent earnings call on 2026-05-18, covering fiscal Q1 2026.